Becton, Dickinson and - BDX Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $267.70
  • Forecasted Upside: 6.07 %
  • Number of Analysts: 8
  • Breakdown:
  • 1 Sell Ratings
  • 3 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$252.38
▲ +1.55 (0.62%)

This chart shows the closing price for BDX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Becton, Dickinson and Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BDX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BDX

Analyst Price Target is $267.70
▲ +6.07% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Becton, Dickinson and in the last 3 months. The average price target is $267.70, with a high forecast of $310.00 and a low forecast of $220.00. The average price target represents a 6.07% upside from the last price of $252.38.

This chart shows the closing price for BDX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 8 polled investment analysts is to hold stock in Becton, Dickinson and. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 4 hold ratings
  • 1 sell ratings
6/12/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 1 sell ratings
9/10/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 1 sell ratings
12/9/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 0 sell ratings
3/9/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
6/7/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 1 sell ratings
9/5/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 1 sell ratings
11/4/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 1 sell ratings
12/4/2022

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/23/2022The Goldman Sachs GroupLower TargetBuy$319.00 ➝ $272.00Low
11/16/2022Evercore ISILower Target$270.00N/A
11/16/2022CowenLower Target$255.00N/A
11/14/2022CitigroupLower Target$227.00 ➝ $220.00Low
11/11/2022William BlairReiterated RatingOutperformLow
11/10/2022Piper SandlerLower TargetNeutral$255.00 ➝ $245.00Low
10/11/2022Morgan StanleyBoost TargetOverweight$272.00 ➝ $275.00Low
10/5/2022CitigroupLower Target$235.00 ➝ $227.00Low
8/16/2022The Goldman Sachs GroupBoost TargetBuy$278.00 ➝ $319.00Low
7/18/2022Stifel NicolausLower Target$290.00 ➝ $280.00Low
7/15/2022Morgan StanleyLower TargetOverweight$282.00 ➝ $272.00Low
7/11/2022CitigroupDowngradeNeutral ➝ Sell$265.00 ➝ $235.00N/A
6/24/2022Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$275.00Low
5/5/2022Piper SandlerLower Target$265.00 ➝ $255.00Low
4/11/2022Morgan StanleyBoost TargetOverweight$293.00 ➝ $295.00Medium
4/1/2022Wells Fargo & CompanyBoost TargetEqual Weight$275.00 ➝ $285.00High
3/28/2022Morgan StanleyLower TargetOverweight$310.00 ➝ $293.00Low
3/1/2022Bank of AmericaInitiated CoverageNeutral ➝ NeutralLow
2/28/2022ArgusBoost Target$275.00 ➝ $310.00Low
2/4/2022Morgan StanleyBoost TargetOverweight$300.00 ➝ $310.00Low
2/4/2022SVB LeerinkBoost TargetMarket Perform$270.00 ➝ $275.00Low
1/7/2022Morgan StanleyBoost TargetOverweight$285.00 ➝ $300.00High
12/8/2021Piper SandlerDowngradeOverweight ➝ Neutral$285.00 ➝ $260.00Medium
10/22/2021SVB LeerinkReiterated RatingMarket PerformLow
8/6/2021SVB LeerinkLower TargetMarket Perform$260.00 ➝ $250.00Medium
8/6/2021JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$276.93 ➝ $265.00Low
7/20/2021SVB LeerinkReiterated RatingMarket PerformLow
5/24/2021BarclaysInitiated CoverageEqual Weight$270.00Medium
5/7/2021SVB LeerinkLower TargetMarket Perform$270.00 ➝ $260.00High
2/5/2021CitigroupBoost TargetNeutral$273.00 ➝ $280.00Low
2/4/2021Piper SandlerBoost TargetPositive ➝ Overweight$275.00 ➝ $280.00Low
1/29/2021Raymond JamesBoost TargetOutperform$270.00 ➝ $282.00Low
12/15/2020The Goldman Sachs GroupDowngradeConviction-Buy ➝ BuyMedium
12/15/2020Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$265.00Medium
12/15/2020Morgan StanleyUpgradeEqual Weight ➝ Overweight$262.00 ➝ $297.00Medium
11/6/2020Morgan StanleyLower TargetEqual Weight$270.00 ➝ $262.00Low
10/12/2020Raymond JamesLower TargetOutperform$285.00 ➝ $270.00Low
10/2/2020The Goldman Sachs GroupUpgradeBuy ➝ Conviction-BuyMedium
8/27/2020Morgan StanleyLower TargetEqual Weight$285.00 ➝ $270.00High
8/10/2020UBS GroupBoost TargetNeutral$265.00 ➝ $280.00Low
8/10/2020Morgan StanleyBoost TargetEqual Weight$248.00 ➝ $285.00Low
8/7/2020Raymond JamesBoost TargetOutperform$265.00 ➝ $285.00Medium
7/15/2020SVB LeerinkBoost TargetMarket Perform$262.00 ➝ $277.00Medium
7/9/2020BarclaysUpgradeEqual Weight ➝ Overweight$300.00Medium
7/2/2020William BlairReiterated RatingOutperformLow
6/25/2020Morgan StanleyLower TargetEqual Weight$255.00 ➝ $248.00High
6/25/2020Raymond JamesLower TargetPositive ➝ Outperform$290.00 ➝ $265.00High
5/31/2020The Goldman Sachs GroupInitiated CoverageBuy$278.00Low
5/14/2020Piper SandlerBoost TargetOverweight$286.00 ➝ $296.00Low
5/12/2020KeyCorpReiterated RatingHoldLow
5/8/2020SVB LeerinkReiterated RatingMarket Perform$245.00 ➝ $262.00Low
5/8/2020CfraLower TargetHold$285.00 ➝ $278.00Medium
5/8/2020UBS GroupBoost TargetNeutral$260.00 ➝ $265.00Medium
5/8/2020Stifel NicolausBoost TargetBuy$265.00 ➝ $280.00Medium
5/8/2020Raymond JamesBoost TargetOutperform$283.00 ➝ $290.00Low
5/8/2020CitigroupBoost TargetNeutral$234.00 ➝ $260.00Low
5/8/2020Wells Fargo & CompanyReiterated RatingBuyLow
4/14/2020BarclaysReiterated RatingHold$266.00Low
4/8/2020SVB LeerinkLower TargetMarket Perform$269.00 ➝ $245.00High
4/8/2020Wells Fargo & CompanyLower TargetOverweight$279.00 ➝ $270.00High
4/1/2020Stifel NicolausLower TargetBuy$280.00 ➝ $265.00Medium
3/27/2020CitigroupLower TargetNeutral$260.00 ➝ $234.00Medium
3/27/2020Morgan StanleyLower TargetEqual Weight$271.00 ➝ $255.00Medium
3/4/2020CitigroupInitiated CoverageNeutral$260.00Medium
2/7/2020Morgan StanleyLower TargetHold ➝ Equal Weight$287.00 ➝ $271.00Medium
2/7/2020Wells Fargo & CompanyLower TargetOverweight$285.00 ➝ $279.00Medium
2/7/2020Raymond JamesDowngradeStrong-Buy ➝ Outperform$288.00 ➝ $283.00Medium
2/6/2020CowenDowngradeOutperform ➝ Market Perform$306.00 ➝ $275.00High
2/6/2020Piper SandlerBoost TargetOverweight$279.00 ➝ $285.00High
2/6/2020CfraDowngradeBuy ➝ Hold$304.00 ➝ $285.00High
2/3/2020CowenReiterated RatingOutperform ➝ Outperform$255.00 ➝ $305.00High
1/22/2020KeyCorpBoost TargetOverweight$284.00 ➝ $298.00Low
1/8/2020BarclaysDowngradeOverweight ➝ Equal Weight$275.00Low
12/20/2019JPMorgan Chase & Co.Boost TargetOverweight$285.00 ➝ $300.00Low
12/17/2019Morgan StanleyBoost TargetEqual Weight$261.00 ➝ $287.00Low
12/16/2019Stifel NicolausBoost TargetBuy$275.00 ➝ $295.00Low
11/13/2019KeyCorpLower TargetOverweight$262.00 ➝ $256.00Medium
9/6/2019Wells Fargo & CompanyBoost TargetOutperform$270.00 ➝ $290.00N/A
9/5/2019Wells Fargo & CompanyReiterated RatingBuyLow
8/6/2019Piper Jaffray CompaniesLower TargetOverweight$267.00 ➝ $266.00Medium
7/16/2019Morgan StanleyBoost TargetEqual Weight$250.00 ➝ $261.00Low
6/28/2019Raymond JamesBoost TargetStrong-Buy$265.00 ➝ $288.00Low
5/13/2019Wells Fargo & CompanyLower TargetOutperform$280.00 ➝ $265.00Low
5/13/2019BarclaysUpgradeEqual Weight ➝ Overweight$266.00Low
5/10/2019BMO Capital MarketsLower TargetMarket Perform$272.00 ➝ $270.00Low
5/10/2019Morgan StanleyLower TargetEqual Weight$255.00 ➝ $250.00High
5/10/2019UBS GroupLower TargetNeutral$265.00 ➝ $250.00High
5/10/2019KeyCorpReiterated RatingPositive ➝ Overweight$273.00 ➝ $262.00High
4/15/2019BarclaysBoost TargetEqual Weight ➝ Equal Weight$260.00 ➝ $266.00Low
3/19/2019Raymond JamesLower TargetStrong-Buy ➝ Strong-Buy$290.00 ➝ $280.00Medium
2/5/2019Piper Jaffray CompaniesBoost TargetOverweight$274.00Low
1/2/2019Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$265.00 ➝ $240.00Low
1/2/2019CitigroupLower TargetBuy ➝ Buy$279.00 ➝ $256.00Low
12/6/2018Deutsche Bank AktiengesellschaftInitiated CoverageBuy ➝ Buy$280.00Medium
11/27/2018UBS GroupInitiated CoverageNeutral$260.00Medium
11/13/2018CitigroupLower TargetBuy ➝ Buy$289.00 ➝ $279.00Low
11/8/2018KeyCorpBoost TargetOverweight ➝ Overweight$264.00 ➝ $273.00Medium
11/8/2018BarclaysSet TargetHold$260.00Medium
11/7/2018Wells Fargo & CompanyLower TargetOutperform$290.00 ➝ $280.00High
11/6/2018Piper Jaffray CompaniesLower TargetOverweight$250.00Medium
10/15/2018BarclaysInitiated CoverageEqual Weight ➝ Equal Weight$278.00High
10/4/2018Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$250.00 ➝ $280.00High
9/6/2018Wells Fargo & CompanyBoost TargetOutperform$275.00 ➝ $290.00Low
8/8/2018CitigroupBoost TargetBuy ➝ Buy$274.00 ➝ $283.00Medium
8/3/2018Royal Bank of CanadaReiterated RatingHold$248.00Low
8/3/2018KeyCorpReiterated RatingBuy$264.00Low
6/21/2018JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$175.00Medium
4/10/2018CitigroupUpgradeNeutral ➝ Buy$237.00 ➝ $251.00Low
3/5/2018BMO Capital MarketsInitiated CoverageMarket Perform$249.00Low
2/7/2018Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$245.00 ➝ $250.00Low
2/6/2018Piper Jaffray CompaniesReiterated RatingOverweight$223.00 ➝ $260.00Low
1/19/2018Bank of AmericaReiterated RatingBuy ➝ Buy$260.00Medium
1/5/2018CitigroupUpgradeSell ➝ NeutralLow
1/5/2018KeyCorpInitiated CoverageOverweight ➝ Overweight$260.00Low
1/3/2018Evercore ISIInitiated CoverageOutperform ➝ Outperform$245.00Medium
12/29/2017Deutsche Bank AktiengesellschaftSet TargetBuy ➝ Buy$239.00 ➝ $260.00Low
12/14/2017ArgusBoost TargetAverage ➝ Buy$235.00Low
(Data available from 12/4/2017 forward)

News Sentiment Rating

0.26 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 9 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/8/2022
  • 8 very positive mentions
  • 24 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/7/2022
  • 8 very positive mentions
  • 24 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
7/7/2022
  • 7 very positive mentions
  • 18 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/6/2022
  • 8 very positive mentions
  • 31 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
9/5/2022
  • 8 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
10/5/2022
  • 6 very positive mentions
  • 15 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
11/4/2022
  • 7 very positive mentions
  • 34 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
12/4/2022

Current Sentiment

  • 7 very positive mentions
  • 34 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Becton, Dickinson and logo
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Read More

Today's Range

Now: $252.38
Low: $247.76
High: $252.59

50 Day Range

MA: $229.49
Low: $218.29
High: $252.38

52 Week Range

Now: $252.38
Low: $215.90
High: $280.62

Volume

1,342,753 shs

Average Volume

1,800,685 shs

Market Capitalization

$71.52 billion

P/E Ratio

42.92

Dividend Yield

1.38%

Beta

0.61

Frequently Asked Questions

What sell-side analysts currently cover shares of Becton, Dickinson and?

The following Wall Street sell-side analysts have issued reports on Becton, Dickinson and in the last twelve months: Argus, Bank of America Co., Citigroup Inc., Cowen Inc., Evercore ISI, Morgan Stanley, Piper Sandler, Stifel Nicolaus, StockNews.com, SVB Leerink LLC, The Goldman Sachs Group, Inc., Wells Fargo & Company, and William Blair.
View the latest analyst ratings for BDX.

What is the current price target for Becton, Dickinson and?

10 Wall Street analysts have set twelve-month price targets for Becton, Dickinson and in the last year. Their average twelve-month price target is $267.70, suggesting a possible upside of 6.1%. Argus has the highest price target set, predicting BDX will reach $310.00 in the next twelve months. Citigroup Inc. has the lowest price target set, forecasting a price of $220.00 for Becton, Dickinson and in the next year.
View the latest price targets for BDX.

What is the current consensus analyst rating for Becton, Dickinson and?

Becton, Dickinson and currently has 1 sell rating, 3 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in BDX, but not buy more shares or sell existing shares.
View the latest ratings for BDX.

What other companies compete with Becton, Dickinson and?

Other companies that are similar to Becton, Dickinson and include Boston Scientific, Stryker, DexCom, ResMed and Baxter International. Learn More about companies similar to Becton, Dickinson and.

How do I contact Becton, Dickinson and's investor relations team?

Becton, Dickinson and's physical mailing address is 1 BECTON DRIVE, FRANKLIN LAKES NJ, 07417. The medical instruments supplier's listed phone number is (201) 847-6800. The official website for Becton, Dickinson and is www.bd.com. Learn More about contacing Becton, Dickinson and investor relations.